New documents have investigators questioning inconsistencies and omissions in data reporting in the PLATO trial, building on ...

A new report questions the efficacy of a drug approved by the FDA to help precent heart attack and stroke in people with a ...

An investigation published in The BMJ raises new concerns over the landmark clinical trial (PLATO) that was used to gain ...

Germany: A recent cohort study published in JAMA Network Open has shed light on the comparative outcomes of ticagrelor and ...

An investigation published by The BMJ today raises new concerns over the landmark clinical trial (PLATO) that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in the ...

A new study supports previous data demonstrating the superiority of prasugrel over ticagrelor in reducing the composite ...

A top selling antiplatelet drug has never quite shaken off doubts about its advantage over cheaper rivals. With generic versions of ticagrelor about to launch, Peter Doshi takes a fresh look at the ...

ICR Healthcare is coordinating meetings on the Company’s behalf. To schedule a meeting with Dr. Phillip Chan, Chief Executive Officer, and Peter J. Mariani, Chief Financial Officer, please send ...

PRINCETON, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...

May delay the effects of oral P2Y 12 inhibitors (eg, clopidogrel, prasugrel, ticagrelor); consider IV form instead. May increase serum amylase.

A new study supports previous data demonstrating the superiority of prasugrel over ticagrelor in reducing the composite outcome of mortality, myocardial infarction, or stroke in patients with acute ...